A female of 70 years of age with type II diabetes, hypertension and NASH is regularly under control in endocrinology and hepatology divisions. She shows no signs of portal hypertension or decompensation. Lab tests include bilirubin (1mg/dl), ALT (70 U/L), AST (60 U/L), ALP (110 U/L), and GGT (87 U/L; ULN 40), normal INR. Ultrasound examination shows liver steatosis without any nodule, no splenomegaly. The question she poses to the hepatologist is if she needs to be included in a surveillance program for early detection of HCC.

What of the following statements are true regarding surveillance for early detection of HCC?